Reports of impending Trump executive order supporting ibogaine research for PTSD drive PBM's continued premarket surge.
Media reports, including from CBS News on April 16, 2026, stated that the White House is drafting an executive order expected to be signed by President Trump as early as that week. The order aims to unlock federal funding and expand U.S. research into ibogaine—a psychedelic compound with potential for treating PTSD, traumatic brain injury, addiction, and related conditions, particularly among veterans—while evaluating its safety and efficacy. This policy signal acted as a clear sector catalyst for companies developing ibogaine or related psychedelic therapies. It built on the company's recent operational progress, including the April 8 expansion of its Australian Phase IIb clinical trial network for natural psilocybin (NPX-5) in palliative care patients with adjustment disorder. The combination sparked explosive retail and momentum-driven buying in this low-float microcap name, with massive volume, multiple trading halts, and follow-through buying overnight and in premarket on April 17.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.